PET scan could predict best drug sequence for advanced breast cancer

NCT ID NCT06595563

Recruiting now Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether a special PET scan (HER2-PET) can help doctors decide which drug to use next in people with advanced HER2-positive breast cancer whose cancer has stopped responding to the drug trastuzumab deruxtecan (T-DXd). About 87 participants will get the scan and be grouped as 'positive' or 'negative' for HER2 activity. Those who are positive will receive a different targeted drug (T-DM1), while those who are negative will get standard care. The goal is to see if the scan can predict who will benefit from switching treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE ADVANCED BREAST CANCER HER2-POSITIVE METASTATIC BREAST CANCER

Contacts and locations

Locations

AZ Delta
NOT_YET_RECRUITING

Roeselare, 8800, Belgium
CHU Charleroi - Marie Curie
NOT_YET_RECRUITING

Charleroi, 6042, Belgium
CHU Liège
NOT_YET_RECRUITING

Liège, 4000, Belgium
Institut Jules Bordet
RECRUITING

Anderlecht, Brussels Capital, 1070, Belgium
UMC Groeningen
NOT_YET_RECRUITING

Groningen, 9713, Netherlands
UZ Gent
NOT_YET_RECRUITING

Ghent, 9000, Belgium
UZ Leuven
NOT_YET_RECRUITING

Leuven, 3000, Belgium
VUMC Amsterdam
NOT_YET_RECRUITING

Amsterdam, 1081, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.